Kenneth F. Blount, Ph.D.
Affiliations: | 2002 | University of Colorado, Boulder, Boulder, CO, United States |
Area:
Biochemistry, General Biophysics, Molecular BiologyGoogle:
"Kenneth Blount"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Olke C. Uhlenbeck | grad student | 2002 | CU Boulder | |
| (Towards defining the conformational isomerizations required for hammerhead ribozyme catalysis.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Orenstein R, Su X, Gonzalez C, et al. (2020) Mo1949 ONE AND DONE? EVALUATION OF EFFICACY FROM A SINGLE ADMINISTRATION OF INVESTIGATIONAL MICROBIOTA-BASED DRUG RBX2660 FOR RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION: COMPARISON TO SINGLE-ADMINISTRATION FECAL MICROBIOTA TRANSPLANT IN PUBLISHED TRIALS Gastroenterology. 158: S-989-S-990 |
| Ray A, Harvey AJ, Gonzalez C, et al. (2020) Mo1930 THE DONOR DOES NOT MATTER IN THE FIGHT AGAINST RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION: RESULTS FROM TWO CLINICAL TRIALS EVALUATING THE SAFETY AND EFFICACY OF INVESTIGATIONAL MICROBIOTA-BASED DRUG RBX2660 Gastroenterology. 158 |
| Blount KF, Shannon WD, Deych E, et al. (2019) Restoration of Bacterial Microbiome Composition and Diversity Among Treatment Responders in a Phase 2 Trial of RBX2660: An Investigational Microbiome Restoration Therapeutic. Open Forum Infectious Diseases. 6: ofz095 |
| Ray A, Mische S, Blount K, et al. (2019) 2822 Twelve-Month Durability of Microbiota-Based Drug RBX2660 for Preventing Clostridioides difficile Infection (CDI) Is Not Associated With Patient Demographics: Sub-Population Analysis of a Phase 2 Open-Label Study The American Journal of Gastroenterology. 114 |
| Orenstein R, Mische S, Blount K, et al. (2019) LB5. A Long-Time Coming: Final 2-year Analysis of Efficacy, Durability, and Microbiome Changes in a Controlled Open-Label Trial of Investigational Microbiota-Based Drug RBX2660 for Recurrent Clostridioides difficile Infections Open Forum Infectious Diseases. 6 |
| Hau H, Mische S, Klein S, et al. (2019) 670. VRE Clearance in Patients with Recurrent Clostridium difficile Infection Following Treatment with Microbiota-Based Drug RBX2660 Open Forum Infectious Diseases. 6 |
| Jones C, Mische S, Blount K, et al. (2019) 669. Twelve-Month Durability of Microbiota-Based Therapy RBX2660 for Prevention of Recurrent Clostridium difficile Infection Open Forum Infectious Diseases. 6 |
| Khanna S, Pardi DS, Gerding DN, et al. (2019) Tu1880 – Durable Freedom from Clostridium Difficile Infection Recurrence and Microbiome Restoration During Six-Month Follow-Up For a Phase 1 Clinical Trial of Rbx7455?An Investigational Room Temperature-Stable, Oral Microbiotabased Therapeutic Gastroenterology. 156 |
| Blount K, Gerding DN, Khanna S, et al. (2019) 624 – Comparison of Two Open-Label Trials Demonstrates Similar 6-Month Outcomes for Rbx2660 and Rbx7455—Investigational Microbiota Restoration Therapeutics Administered by Enema Or Oral Capsules for Preventing Recurrent Clostridium Difficile Infections Gastroenterology. 156 |
| Vicens Q, Mondragón E, Reyes FE, et al. (2018) Structure-activity relationship of flavin analogs that target the FMN riboswitch. Acs Chemical Biology |